• Explore /
  • Poster
  • / A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma.

A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma.

Abstract Poster

Authors

null

Nicholas A. Butowski

University of California, San Francisco, San Francisco, CA

Nicholas A. Butowski , Howard Colman , John Frederick De Groot , Antonio Marcilio Padula Omuro , Lakshmi Nayak , Timothy F. Cloughesy , Adhirai Marimuthu , Arie Perry , Joanna J Phillips , Brian West , Michael Prados , Keith B. Nolop , Henry H Hsu , Keith L. Ligon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

NCT01349036

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 2023)

DOI

10.1200/jco.2014.32.15_suppl.2023

Abstract #

2023

Poster Bd #

14

Abstract Disclosures

Similar Posters

Poster

2011 ASCO Annual Meeting

Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit.

Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit.

First Author: S. P. Anthony

First Author: Patrick Y. Wen

First Author: Yoshitaka Narita

First Author: Martin J. Van Den Bent